Risultati per: Carcinoma della prostata

Previene metastasi e morte in malati ad alto rischio di recidive

Previene metastasi e morte in malati ad alto rischio di recidive

In Reply We appreciate the comments from Shigematsu and Inamura regarding our cohort study on atezolizumab antidrug antibody (ADA). We would like to address their valuable comments.

To the Editor Active surveillance (AS) for low-risk papillary thyroid carcinoma (PTC) has been a focus of research and debate. Recently in JAMA Oncology, Ho and colleagues reported the result of patients with 20-mm or smaller thyroid nodules who chose either AS or immediate surgery. This nonrandomized controlled trial provided new evidence for the management of low-risk PTC. Here, we raise concerns about the study’s design and interpretation of the results.

To the Editor We read with great interest the cohort study by Kim and colleagues and appreciate the authors’ efforts to determine the adverse prognostic association of high-level serum antidrug antibody (ADA) against atezolizumab in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab and bevacizumab. We have 3 concerns regarding the interpretation of the findings and hope that the authors would consider them.

In Reply We thank Yang and colleagues for their interest in our nonrandomized controlled trial comparing active surveillance (AS) with immediate surgery (IS) for papillary thyroid carcinoma (PTC). The authors correctly note that guidelines such as those from the American Thyroid Association support AS for PTCs 10 mm or smaller. Our study’s primary purpose was to investigate the safety of AS for tumors falling outside of these standard guidelines in the context of a clinical trial. We elected to study up to 20 mm because this captures all T1 cancers. To our knowledge, there is no biologic distinction between cancers within this stage grouping. Since AS was investigational at the time of study onset, we limited inclusion to 15-mm cancers out of an abundance of caution; we later expanded to all T1 tumors in conjunction with observational data from other groups studying this approach.

This cohort study aims to determine how Merkel cell carcinoma presentation and outcomes differ across racial and ethnic groups.

This phase 2 randomized clinical trial evaluates whether the addition of vistusertib to weekly paclitaxel improves clinical outcomes in patients with platinum-resistant ovarian high-grade serous carcinoma.

This case report describes hyperpigmented, indurated, and sclerotic plaques on the anterior trunk and upper abdomen with overlying scale that were studded with firm, erythematous papules.

Objectives
To compare the prognostic values of three lymph node staging systems in renal cell carcinoma (RCC), including the number of positive lymph nodes (NPLN), lymph node ratio (LNR) and log odds of positive lymph nodes (LODDS).

Design
A retrospective cohort study using data from the Surveillance, Epidemiology and End Results (SEER) database.

Setting and participants
1904 patients with pathological N1 RCC, diagnosed from 2004 to 2015 and underwent nephrectomy combined with lymph node dissection, were identified from the SEER database.

Primary outcome measure
The primary outcome of this study was overall survival (OS). Restricted cubic spline functions and multivariable Cox regression analyses were employed to characterise the associations of OS with NPLN, LNR and LODDS, respectively.

Results
Data of 1904 eligible RCC patients were extracted from the SEER database. The mortality risks of RCC patients increased with the increasing of NPLN, LNR and LODDS. NPLN (NPLN3 vs NPLN1, HR 1.22, 95% CI 1.05 to 1.43, p=0.001), LNR (LNR3 vs LNR1, HR 1.46, 95% CI 1.28 to 1.67, p

Con 2 milioni di euro. Test su ‘gemelli’ di organi per migliorare le cure

Grazie alla Biopsia Fusion, con 100 mila euro di investimento

Gastric cancer (GC) is a major cancer type characterized by high heterogeneity in both tumor cells and the tumor immune microenvironment (TIME). One intractable GC subtype is gastric signet-ring cell carcinoma (GSRCC), which is associated with poor prognosis. However, it remains unclear what the GSRCC TIME characteristics are and how these characteristics may contribute to clinical outcomes.

Nel 2022 in Italia 40.500 diagnosi. +16% in cinque anni